Savara, Inc. (SVRA)
4.22
-0.32
(-7.05%)
USD |
NASDAQ |
Oct 23, 16:00
4.28
+0.06
(+1.42%)
After-Hours: 20:00
Savara Enterprise Value : 724.16M for Oct. 23, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 23, 2026 | 724.16M |
| October 22, 2026 | 789.89M |
| October 21, 2026 | 816.59M |
| October 20, 2026 | 835.07M |
| October 19, 2026 | 808.37M |
| October 16, 2026 | 771.40M |
| October 15, 2026 | 830.97M |
| October 14, 2026 | 835.07M |
| October 13, 2026 | 839.18M |
| October 12, 2026 | 851.51M |
| October 09, 2026 | 867.94M |
| October 08, 2026 | 849.45M |
| October 07, 2026 | 859.72M |
| October 06, 2026 | 812.48M |
| October 05, 2026 | 839.18M |
| October 02, 2026 | 845.34M |
| October 01, 2026 | 893.61M |
| September 30, 2026 | 917.23M |
| September 29, 2026 | 900.80M |
| September 28, 2026 | 898.75M |
| September 25, 2026 | 884.37M |
| September 24, 2026 | 898.75M |
| September 23, 2026 | 884.37M |
| September 22, 2026 | 945.99M |
| September 21, 2026 | 976.80M |
| Date | Value |
|---|---|
| September 18, 2026 | 960.37M |
| September 17, 2026 | 970.64M |
| September 16, 2026 | 911.07M |
| September 15, 2026 | 937.77M |
| September 14, 2026 | 954.21M |
| September 11, 2026 | 945.99M |
| September 10, 2026 | 950.10M |
| September 09, 2026 | 969.61M |
| September 08, 2026 | 993.23M |
| September 04, 2026 | 960.37M |
| September 03, 2026 | 960.37M |
| September 02, 2026 | 978.85M |
| September 01, 2026 | 956.26M |
| August 31, 2026 | 964.48M |
| August 28, 2026 | 937.77M |
| August 27, 2026 | 985.02M |
| August 26, 2026 | 1.010B |
| August 25, 2026 | 1.008B |
| August 24, 2026 | 999.39M |
| August 21, 2026 | 1.006B |
| August 20, 2026 | 985.02M |
| August 19, 2026 | 1.004B |
| August 18, 2026 | 960.37M |
| August 17, 2026 | 960.37M |
| August 14, 2026 | 962.42M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Gilead Sciences, Inc. | 214.93B |
| Insmed, Inc. | 19.97B |
| United Therapeutics Corp. | 22.41B |
| Vertex Pharmaceuticals, Inc. | 126.85B |
| ACADIA Pharmaceuticals, Inc. | 2.514B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -40.23M |
| Total Expenses (Quarterly) | 40.23M |
| EPS Diluted (Quarterly) | -0.1587 |
| Earnings Yield | -13.66% |
| Normalized Earnings Yield | -13.66 |